Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency - Wikidata - awgldk - TriplyDB

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

http://www.wikidata.org/entity/Q34112793

about

Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies.Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency.Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Bioavailability of IgG administered by the subcutaneous route.Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States.Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.Immunoglobulin G promotes skin graft acceptance in an immunologically potent rat model.Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Bringing immunoglobulin knowledge up to date: how should we treat today?Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.Modern management of primary B-cell immunodeficiencies.Safety of L-proline as a stabilizer for immunoglobulin products.Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders.The expanding role of therapeutic antibodies.Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.Hizentra for the treatment of primary immunodeficiency.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.Management of common variable immunodeficiency by subcutaneous IgG self-administration during pregnancy - a case report.Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response.Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.New Frontiers in Subcutaneous Immunoglobulin Treatment.Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy.Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam®, in primary immunodeficiency.

P2860

Q33419638-17CF9E73-E831-4C4E-8724-8DBB0C127110 Q33849464-75365533-2E13-404D-83A8-5FD8AC6EF6B1 Q34196132-1E2C44E9-21B2-4E44-B2F2-350F1442F36C Q34196146-EB7D2B06-CDDF-4352-9C6C-A37F4438B0AE Q35566525-EA008DA6-83F7-46D8-A08A-DF8EBBDDFC87 Q35834812-3F93CB50-E5A6-4A71-8E74-A249DD5E4586 Q36065396-04FF770A-9661-4915-9391-92123BD2C0C5 Q36121067-1B6A64E9-8E64-4227-8761-4B8F41341E31 Q36149327-4A9FCBD8-CCDB-4CBA-AD9F-F9378805C717 Q36196688-42257A65-B6E8-460B-A719-DA0A1A186B9D Q36927579-0C42FE68-7F48-4FC0-B204-DB668357D29A Q36949416-A1C851CF-5428-4AF6-BA64-5D2E9632D73D Q37083973-19A344EE-6FBA-44CE-8237-7AF3F901348C Q37246362-593F05AD-CF39-42E0-B2AF-FA100182544B Q37457538-FDA74AB6-087A-479B-8850-A82450239E4B Q37514512-D0FC2E85-8AEC-4FE3-AF6E-03595CAD7D03 Q37608261-DD889A20-6FD0-4134-A649-F3D4A6020670 Q37861872-1BCDADD4-E0D1-499B-B1C4-EB2350BF1E01 Q37890936-C4819F33-F4C4-43A7-B5BD-B84AE82DC7EB Q37901520-4D42C9D4-EE95-4328-BABA-F83898E318F7 Q37929510-886FB68D-B915-4943-8B68-246025598F6C Q37962045-168F553B-AD9E-4159-AD27-8FFF7E09D3CA Q37979844-17CE8055-4684-44B8-840C-A3BCC8D3BECF Q38012531-3CC2823B-FBF3-403E-AB17-FDC4177C4083 Q38182645-4C86CC08-2090-413A-9B0D-C280C3E6F2CB Q38217591-6F4D3825-FC57-4F03-993D-E5641AEDBDD2 Q38245612-A751985C-316D-4C3E-8D7B-C8D7F09FAACA Q38266635-DC04811F-D2BF-4457-95A7-B606A837910E Q38744512-5E3F4D6E-88E3-4094-B5A9-657A0E74D743 Q39122007-D334EC2D-8A51-4998-8C5B-2151AC156D1D Q40104668-650FE910-61B3-435C-A7FF-3C1FCDDD20C2 Q40165686-A2FD6704-D9FE-4502-8A87-1E5D32E95E65 Q40596658-4ED8699B-4815-420E-A0FF-D24C5759C7DC Q42251007-2579D031-C081-46BF-87A3-C6CEE9B04CEC Q42608614-4CA8E764-498A-497F-B3E1-7A732F8B03B5 Q42775420-A0301FB8-31F6-4E29-B6AA-CBD854B589A4 Q45762968-C38F454F-407F-4222-9B15-76025F6A0DD1 Q46002738-D56707F0-D310-4FEF-A9CB-0E1F58A63E3C Q47217747-59884CDE-E359-4910-8236-23CF4862D026 Q48451728-FFE9D2AC-4CE7-47F2-9B78-D6C3D0E43DD6

P2860

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

http://www.wikidata.org/entity/Q34112793

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@ast

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@en

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@nl

type

label

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@ast

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@en

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@nl

prefLabel

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@ast

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@en

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@nl

P1433

Q34112793-223F6A20-C862-4258-8F66-A7DC36868A5F

P1476

Q34112793-9B6DE0C8-DFA6-43F6-ABDB-D54068BEC522

P2093

Q34112793-27B5EA59-8A55-4921-83B7-75C63BA90764

Q34112793-6856CB66-23F7-4767-8595-F5010F70E009

Q34112793-6C18C3A9-5F5B-4F94-9471-D90CEDA311A4

Q34112793-835705D6-6175-40F1-9C29-6F21172138DB

Q34112793-96B040CC-AEDF-4377-B16A-231F8AEAEF44

Q34112793-D7F5B1EA-219B-4702-A1D6-7C1A2761D74F

Q34112793-E716012A-CB1C-46AC-987F-C5587BFEC4D4

P2860

Q34112793-003ABD01-E83E-4B2F-9211-6909BE432095

Q34112793-008D15A9-144A-415D-B91E-8389A4E8CD10

Q34112793-059088BA-6895-498F-8D98-86E8030C0207

Q34112793-05A3BE8C-0883-46FB-883E-0287D133D70E

Q34112793-1A596549-EB11-498D-85A9-E7D6415B0EA8

Q34112793-1E60F171-F2BE-42D7-9F17-CD72B9FDFD82

Q34112793-2CC92C8B-A9B5-4FDE-8C9A-9D09E3B24EC3

Q34112793-34AD2D67-BCEE-4E5A-ABCC-6E311C40E698

Q34112793-403DD669-FE37-4F12-ABA2-0DA3841FF533

Q34112793-435F8A7C-40B7-4DBB-A6A1-DDE3719D9813

P2888

Q34112793-C8FA6471-4127-4B52-AA99-BD37789EB386

P304

Q34112793-78D8EE91-9F51-463D-A9B9-37EFCB93E401

P31

Q34112793-C4443A56-856A-45E4-9A6C-9456DB80516A

P356

Q34112793-A9C5AB90-C3FC-49F7-B031-76AE61C10DB8

P433

Q34112793-0125ADA2-61B1-45FE-B44D-E657081AFEC3

P478

Q34112793-B34050E4-D722-4039-A0DB-860006C7F2FC

P50

Q34112793-A4A60149-9785-405B-8564-793D45769C9E

P577

Q34112793-EF97863F-3749-450C-A60C-685CDABC9388

P5875

Q34112793-B57C9DFB-C848-4ECA-9A74-9EDB6DF3F81D

P6179

Q34112793-B2A426CF-202C-494C-BE47-178452FC1A1C

P698

Q34112793-65E7E728-4B3C-47F0-8572-5BC0B66B79E6

P921

Q34112793-554BF376-EBB2-46D5-B151-BE9B1667B0FA

P932

Q34112793-CCF3EE3A-1661-423A-AF5C-0891B21D2A5A

P356

S10875-010-9423-4

P1433

Journal of Clinical Immunology

P1476

Efficacy and safety of a new 2 ...... with primary immunodeficiency

@en

P2093

Isaac Melamed

http://www.w3.org/2001/XMLSchema#string

John B Hagan

http://www.w3.org/2001/XMLSchema#string

Mary B Fasano

http://www.w3.org/2001/XMLSchema#string

Mikhail A Rojavin

http://www.w3.org/2001/XMLSchema#string

Othmar Zenker

http://www.w3.org/2001/XMLSchema#string

Richard L Wasserman

http://www.w3.org/2001/XMLSchema#string

Sheldon Spector

http://www.w3.org/2001/XMLSchema#string

P2860

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.

Primary immunodeficiency diseases due to defects in lymphocytes.

Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies.

Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.

Common variable immunodeficiency: a new look at an old disease.

Subcutaneous administration of IgG.

The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies.

Human intravenous immunoglobulin in primary and secondary antibody deficiencies.

P2888

s10875-010-9423-4

P304

734-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10875-010-9423-4

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44584858

http://www.w3.org/2001/XMLSchema#string

P6179

1030881751

http://www.w3.org/2001/XMLSchema#string

P698

20454851

http://www.w3.org/2001/XMLSchema#string

P921

P932

2935975

http://www.w3.org/2001/XMLSchema#string